Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss a new Bank of America report showing the implications of closing wealth gaps.
Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss a new Bank of America report showing the implications of closing wealth gaps.
The BBC's Diversity Manager said of DCI John Luther, "he doesn't have any Black friends, he doesn't eat any Caribbean food, this doesn't feel authentic."
Made by “Marcella” producer Buccaneer Media as an original for AMC’s BritBox rival Acorn TV, “Whitstable Pearl” has all the ingredients of a travel-friendly crime series with a female lead in a picturesque English town. And while the six part, 45-minute series slots in neatly with the streamer’s other small town crime canon, including Cotswold’s based […]
Democrats in the U.S. House of Representatives on Wednesday will try to advance a bill that could lead to reparations for Black Americans as part of a broader effort to address centuries of enslavement followed by modern-day institutional racism. It faces an uphill climb in Congress, where prominent Republicans oppose the measure and none have joined the 175 Democrats who signed on as co-sponsors. Representative Jim Jordan, the senior Republican on the House Judiciary Committee that is scheduled to vote on the measure on Wednesday, intends to oppose it, an aide said.
Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Anti-obesity Drugs Market Forecast 2020-2030" - https://www.reportlinker.com/p04763516/?utm_source=GNW The global anti-obesity drugs market is estimated to have reached $1.9bn in 2019 and is expected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the innovator drugs submarket held 75% of the global anti-obesity drugs market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 285-page report you will receive 146 tables and 137 figures– all unavailable elsewhere. The 285-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act. Report Scope ? Global Anti-obesity Drugs Market forecast from 2020-2030 ? Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action: ? Incretion mimetics/GLP-1 agonists ? SNDRIs ? Lipase Inhibitors ? Serotonin receptor agonists ? Sympathomimetic-GABA receptor agonists ? Sympathomimetics ? Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Duration of Therapy: ? Long-term Drugs ? Short-term Drugs ? Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Innovator vs Generic Drugs: ? Innovator ? Generic Drugs ? Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Prescription vs OTC: ? Prescription Drugs ? OTC ? This report discusses and provides revenue forecasts from 2020-2030 for selected anti-obesity drugs: ? Saxenda ? Contrave/Mysimba ? Belviq ? Qysmia ? Xenical ? Alli ? This report provides individual revenue forecasts from 2020-2030 for these regional and national markets: ? US ? Japan ? EU5: Germany, France, Spain, Italy, UK ? BRIC: Brazil, Russia, China, India ? RoW Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs. ? Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market: ? Arena Pharmaceuticals ? AstraZeneca ? Carmot Therapeutics ? CohBar ? Currax Pharmaceuticals LLC ? Eisai ? ERX Pharmaceuticals ? Gelesis ? GlaxoSmithKline (GSK) ? Hanmi Pharmaceutical ? LNC Therapeutics ? Novartis ? Novo Nordisk ? Pfizer ? Rhythm Pharmaceuticals, Inc. ? Roche ? Saniona ? Scohia Pharma, Inc. ? Sinil Pharmaceutical Co., Ltd ? Takeda ? Teva ? Vivus ? This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules. ? This report gives an overview of pricing and reimbursement in the US and EU. ? This report provides a SWOT Analysis of the global anti-obesity drugs market. ? Key questions answered by this report: ? How is the anti-obesity drugs market evolving? ? What is driving and restraining anti-obesity drugs dynamics? ? How will each anti-obesity drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2030? ? How will market shares of each anti-obesity drugs submarket develop from 2020-2030? Which individual technologies will prevail and how will these shifts be responded to? ? Which anti-obesity drugs submarket will be the main driver of the overall market from 2020-2030? ? How will political and regulatory factors influence regional anti-obesity drugs markets and submarkets? ? Will leading national anti-obesity drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy? ? How will market shares of the national markets change by 2030 and which nation will lead the market in 2030? ? Who are the leading players and what are their prospects over the forecast period? ? How will the sector evolve as alliances form during the period between 2020 and 2030? This study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.Read the full report: https://www.reportlinker.com/p04763516/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Queer Eye fashionista Tan France has revealed that he and his husband are expecting their first child via a surrogate. The Doncaster-born star told fans on Instagram that he and his partner, Rob, will become parents in the summer. France, 37, shared a photo of himself holding a superimposed ultrasound over his stomach to reveal the news.
The "Silicon on Insulator Market by Wafer Size, Wafer Type, Technology, Product and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
The Dipi Rebecchi actor speaks out about her time on the soap.
Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Global Coronavirus Partnering 2014-2021" report has been added to ResearchAndMarkets.com's offering. The Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.The report takes readers through the comprehensive Coronavirus disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Coronavirus deals.The report presents financial deal terms values for Coronavirus deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.The initial chapters of this report provide an orientation of Coronavirus dealmaking trends.Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in Coronavirus dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.Chapter 4 provides a review of the leading Coronavirus deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 5 provides comprehensive access to Coronavirus deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014. The chapter is organized by specific Coronavirus therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.In addition, a comprehensive appendix is provided with each report of all Coronavirus partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Global Coronavirus Partnering 2014 to 2021 includes: Trends in Coronavirus dealmaking in the biopharma industry since 2014Access to headline, upfront, milestone and royalty dataAccess to hundreds of Coronavirus deal contract documentsComprehensive access to over 1000 Coronavirus deal recordsThe leading Coronavirus deals by value since 2014Most active Coronavirus dealmakers since 2014 In Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by: Headline valueUpfront payment valueRoyalty rate valueStage of development at signingDeal component typeTechnology typeSpecific therapy indication Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How are the sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in Coronavirus dealmaking2.1. Introduction2.2. Coronavirus partnering over the years2.3. Coronavirus partnering by deal type2.4. Coronavirus partnering by industry sector2.5. Coronavirus partnering by stage of development2.6. Coronavirus partnering by technology type2.7. Coronavirus partnering by therapeutic indicationChapter 3 - Financial deal terms for Coronavirus partnering3.1. Introduction3.2. Disclosed financials terms for Coronavirus partnering3.3. Coronavirus partnering headline values3.4. Coronavirus deal upfront payments3.5. Coronavirus deal milestone payments3.6. Coronavirus royalty ratesChapter 4 - Leading Coronavirus deals and dealmakers4.1. Introduction4.2. Most active in Coronavirus partnering4.3. List of most active dealmakers in Coronavirus4.4. Top Coronavirus deals by valueChapter 5 - Coronavirus contract document directory5.1. Introduction5.2. Coronavirus partnering deals where contract document availableChapter 6 - Coronavirus dealmaking by therapeutic target6.1. Introduction6.2. Deals by Coronavirus therapeutic targetFor more information about this report visit https://www.researchandmarkets.com/r/8tniik CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Tauriga 04-14-2021 Pomegranate Blister Pack Design: 25mg CBD Tauri-Gum™ NEW YORK, NY, April 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has received substantial Pre-Orders for its new, 25mg CBD & CBG infused Tauri-Gum™ versions. The enhanced 25mg CBD & CBG infusion concentrations apply to five distinct Tauri-Gum™ SKUs: Mint (CBD), Blood Orange (CBD), Pomegranate (CBD), Peach-Lemon (CBG), and Black Currant (CBG). CBD = CANNABIDIOL CBG = CANNABIGEROL The Company has made the following strategic decision: There will be No Increase in Tauri-Gum™ Retail Prices (“MSRP”). The Company has been successful in reducing costs (basic factors of production costs), pursuant to the Tauri-Gum™ manufacturing process. Lastly, the Company has generated strong E-Commerce sales during the first two weeks of April 2021. Between the Pre-Orders (25mg Tauri-Gum™) and its strong E-Commerce sales, the Company is confident in its growth prospects for Fiscal Year 2022 (Period: April 1, 2021 – March 31, 2022). ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc.4 Nancy Court, Suite 4Wappingers Falls, NY 12590Chief Executive OfficerMr. Seth M. ShawEmail: firstname.lastname@example.org # (917) 796 9926Company Instagram: @taurigumPersonal Instagram: @sethsms47Twitter: @SethMShawCorp. Website: www.tauriga.comE-Commerce Website: www.taurigum.com Attachment Tauriga 04-14-2021
Only 54% of rents that collectors were owed from retailers was collected last month.
This is the second Delhi Capitals player to be tested positive for Coronavirus.
Ryanair on Wednesday had another setback in its fight against state aid for rival airlines after Europe's second-highest court again backed EU competition regulators' approval of support for SAS and Finnair. Europe's biggest budget airline has filed 16 lawsuits against the European Commission for allowing state aid to individual airlines such as Lufthansa, KLM, Austrian Airlines and TAP, as well as national schemes that mainly benefit flag carriers. The Luxembourg-based General Court said aid granted to SAS and Finnair complied with the bloc's state aid rules.
President Joe Biden's nominees to lead the Justice Department's civil rights and environmental units are due to face questions from the Senate Judiciary Committee on Wednesday on how they would address racial inequities in policing and climate change. Kristen Clarke, a former Justice Department civil rights attorney who recently led the Lawyers' Committee for Civil Rights Under Law, is Biden's nominee to serve as assistant attorney general for the Civil Rights Division.
MercadoLibre (NASDAQ: MELI), Latin America's largest e-commerce company, has seen its share price almost triple over the last year. The company was already growing rapidly before the pandemic, and the crisis accelerated digital adoption and pushed the continent to embrace online payments and e-commerce like never before. The company's numbers demonstrate the strength of this trend.
Nearly a year after President Joe Biden called for "real action" on police brutality as part of a pledge to fix U.S. racial inequality, he is coming up against the limits of presidential power. The White House shelved a proposed police oversight commission this week to focus on a police reform bill that has narrow hopes in Congress. The move comes as anger grows over the killing of another Black man, Daunte Wright, who was stopped by police just miles from where George Floyd was killed last May.
The conflict between Hood County residents living near Rucker Creek and Granbury officials over a sewage treatment plant is far from over.
As the rapid growth of esports cultivates a unique gaming culture for esports athletes, fans and more, HyperX is committed to empowering women in gaming and inspiring all gamers to achieve their best. With a focus on increasing access and representation for the next gen of talent in the gaming industry, HyperX continues to support initiatives internally and externally, including its partnership with the 1,000 Dreams Fund’s BroadcastHER Academy which enables 10 talented women selected for the 2021 Academy Fellowship Program. The alliance is also on the heels of joining forces with 2019 WNBA Champion Aerial Powers as a member of the HyperX Hero family of ambassadors who uses her voice to elevate the need for diversity and inclusion in all spaces, including esports and gaming.
People returning from holidays in ‘green’ countries will not be required to self-isolate under the new traffic light system.
After several months of training, 16 teenagers from different neighbourhoods of the eastern French city of Metz are determined to test their limits and build confidence. To that end, they took up arms in a war of words: a public speaking competition. The Banlieue Project team went to meet them.
New York, New York--(Newsfile Corp. - April 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders Ebix, Inc. (NASDAQ: EBIX).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/ebix-inc-loss-submission-form/?id=14688&from=5Affected shareholders purchased shares of EBIX between November 9, 2020 and February 19, 2021Shareholders interested in representing the class of wronged shareholders have until April 23, 2021 to petition the court. Your ability to share in any recovery doesn't require that ...